Kirk Malloy Net Worth

The estimated Net Worth of Kirk Malloy is at least $327 Thousand dollars as of 6 May 2024. Kirk Malloy owns over 41,133 units of Nanostring Technologies Inc stock worth over $6,885 and over the last 20 years he sold NSTG stock worth over $124,474. In addition, he makes $195,979 as Independent Director at Nanostring Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Kirk Malloy NSTG stock SEC Form 4 insiders trading

Kirk has made over 20 trades of the Nanostring Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 41,133 units of NSTG stock worth $4,331 on 6 May 2024.

The largest trade he's ever made was exercising 41,133 units of Nanostring Technologies Inc stock on 6 May 2024 worth over $4,331. On average, Kirk trades about 2,642 units every 49 days since 2005. As of 6 May 2024 he still owns at least 65,384 units of Nanostring Technologies Inc stock.

You can see the complete history of Kirk Malloy stock trades at the bottom of the page.

Kirk Malloy biography

Dr. Kirk D. Malloy Ph.D. serves as Independent Director of the Company. Dr. Malloy served as Chief Executive Officer of Verogen, Inc., from August 2017 to August 2018 after founding the company and securing initial funding. Dr. Malloy is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics, and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as Senior Vice President and General Manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013 he served as Vice President of Global Customer Solutions; he was also Vice President of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as Senior Director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Diagnostics and QIAGEN Inc. Dr. Malloy currently serves as Chairman of the Board for Organovo, a publicly-traded company that designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. He also serves as a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University. Malloy is qualified to serve as a director of NanoString because of his extensive experience with more than 20 years of commercial leadership in life science tools, applied markets, and molecular diagnostics.

What is the salary of Kirk Malloy?

As the Independent Director of Nanostring Technologies Inc, the total compensation of Kirk Malloy at Nanostring Technologies Inc is $195,979. There are 15 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.

How old is Kirk Malloy?

Kirk Malloy is 53, he's been the Independent Director of Nanostring Technologies Inc since 2016. There are 13 older and 4 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.

What's Kirk Malloy's mailing address?

Kirk's mailing address filed with the SEC is 530 FAIRVIEW AVENUE N, , SEATTLE, WA, 98109.

Insiders trading at Nanostring Technologies Inc

Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus..., and Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.

What does Nanostring Technologies Inc do?

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

Complete history of Kirk Malloy stock trades at Illumina Inc, Nanostring Technologies Inc, Organovo Inc, and DermTech

Nanostring Technologies Inc executives and stock owners

Nanostring Technologies Inc executives and other stock owners filed with the SEC include:

• R. Bradley Gray,
  President, Chief Executive Officer, Director
• K. Thomas Bailey,
  Chief Financial Officer
• Joseph Beechem,
  Senior Vice President - Research and Development
• John Brown,
  Senior Vice President - Sales and Marketing
• David Ghesquiere,
  Senior Vice President - Corporate and Business Development
• R. Bradley Gray,
  CEO, Pres & Director
• K. Thomas Bailey M.B.A.,
  Chief Financial Officer
• Dr. Joseph M. Beechem,
  Chief Scientific Officer and Sr. VP of R&D
• J. Chad Brown,
  Sr. VP of Sales & Marketing
• David W. Ghesquiere,
  Sr. VP of Corp. & Bus. Devel.
• William Young,
  Independent Chairman of the Board
• Gregory Norden,
  Independent Director
• Don Kania,
  Independent Director
• Charles Waite,
  Independent Director
• Elisha Finney,
  Independent Director
• Kirk Malloy,
  Independent Director
• Robert Hershberg,
  Independent Director
• Elizabeth Schneider Ph.D.,
  Sr. Global Marketing Mang.
• Dr. Philippa Webster Ph.D.,
  Sr. Principal Scientist
• Dr. Mary Tedd Allen,
  Sr. VP of Strategic Initiatives
• Kathryn Surace-Smith,
  Sr. VP of HR & Legal Affairs and Corp. Sec.
• Douglas S. Farrell,
  VP of Investor Relations & Corp. Communications
• Mark A. Winham,
  Sr. VP of Operations
• Teresa M. Foy,
  Director
• Nicholas Galakatos,
  Director
• Lifesciences Ii, L.P.Clarus...,
  
• Wayne Burns,
  SVP, Operations & Admin
• James A Johnson,
  Chief Financial Officer
• J. Chad Brown,
  SVP, Sales & Marketing
• Mary Tedd Allen,
  SVP, Operations
• Lifesciences Ii, L.P.Clarus...,
  
• Barney Saunders,
  SVP & GM, Life Sciences
• Venture Partners Vi Lpovp V...,
  
• Fisher Jurvetson Fund Vii, ...,
  
• Finny Kuruvilla,
  Director
• Tina Susan Nova,
  Director
• Bruce J. Seeley,
  SVP & GM, Diagnostics
• J Wayne Cowens,
  Chief Medical Officer
• Jennifer Scott Fonstad,
  Director
• Bradford Crutchfield,
  Director
• Janet George,
  Director
• Dana E. Rollison,
  Director
• John D. Gerace,
  Chief Commercial Officer
• Jonathan Todd Garland,
  Chief Commercial Officer